SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001

The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers
and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut. The study plans to
enroll 36 healthy volunteers for multiple ascending dosing of SNIPR001 (NCT05277350). SNIPR001
has been granted Fast-Track designation by the FDA and is being developed in collaboration with the
US non-profit organization CARB-X.
With the initiation of the First-in-Human study SNIPR BIOME becomes a clinical stage company. The
experimental CRISPR therapeutic, SNIPR001, is designed to selectively target and eradicate E. coli in
the gut, thus preventing translocation of these bacteria to the bloodstream, in a high-risk population
of hematological cancer patients at risk for neutropenia. This precision approach could transform the
way E. coli infections are prevented and treated, especially in the cancer ward. Today, there are no
approved therapies for prophylactic therapy in this setting.
”Today, is a very special moment for SNIPR BIOME. For the first time ever, we are dosing a CRISPRdrug
candidate in humans. Getting to this point is a major achievement and I am extremely proud of
the whole SNIPR BIOME team, our collaborators, and advisors and especially our skilled CMC partner,
Jafral, for their relentless effort in successfully bringing our first CRISPR-medicine into humans.
However, this is only the beginning, and we truly believe that SNIPR001 could have the potential to
help hematological cancer patients at increased risk of life-threatening bloodstream infections caused
by multidrug resistant E. coli”, says Dr. Christian Grøndahl, Co-founder & CEO.

Dr. Milan Zdravkovic, Chief Medical Officer and Head of R&D at SNIPR Biome, comments: “We are
excited about having brought our first asset into humans and expect top line results around year-end.
We are in parallel pursuing our pipeline of CRISPR-medicines of exciting targets within oncology,
immunology and cardio-metabolism, and have an ambition of selecting the next molecule from our
pipeline to move into IND enabling studies also by the end of this year”
For more information, please contact:
Christian Grøndahl, Dr.Med, Co-founder and CEO
E-mail: cg@sniprbiome.com
Mobile: +45 20202747
www.sniprbiome.com
Please follow us on LinkedIn & Twitter: @sniprbiome

About SNIPR BIOME
SNIPR BIOME is a leading CRISPR, and microbiome biotech company incorporated in Copenhagen,
Denmark. SNIPR BIOME is engaged in the discovery and development of CRISPR/Cas-based medicines
deploying its proprietary and patent-protected CRISPR/Cas platform. The company applies its CRISPR
technologies to selectively target microbial pathogens and remodel the microbiome to address
important unmet medical needs. SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to
selectively and precisely eradicate target bacteria, while leaving the rest of the patient’s microbial
community intact. SNIPR BIOME was recently awarded a several million-dollar grant by CARB-X for
CRISPR-based treatment of haematological cancer patients at risk of neutropenic fever and lifethreating
infections (SNIPR001). In addition, SNIPR BIOME and The University of Texas MD Anderson
Cancer Center has a strategic collaboration agreement to advance new CRISPR-based microbiome
therapeutics to reduce immune-related adverse events (irAE) in patients being treated with combined
immune checkpoint inhibitors. The company also develops proprietary technologies for in
situ production of therapeutics in the human microbiome. SNIPR BIOME and Novo Nordisk recently
entered into a research agreement on an undisclosed target to evaluate this technology for gene
therapy of the microbiome i.e., in situ production of therapeutics in the human microbiome. SNIPR
BIOME holds an extensive portfolio of granted patents protecting CRISPR modification of microbiota
as an adjunct to cancer therapy, vaccine therapy and other immunotherapies. In March 2019, SNIPR
BIOME closed a $50 million Series A financing by Lundbeckfonden Emerge (Copenhagen), Life Sciences
Partners (Amsterdam), North-East Family Office (Copenhagen) and Wellington Partners (Munich).
For more details, please visit: www.sniprbiome.com and follow us on LinkedIn & Twitter:
@sniprbiome

About CARB-X
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global nonprofit
partnership dedicated to supporting early development antibacterial R&D to address the rising
threat of drug-resistant bacteria. CARB-X is led by Boston University and funding is provided by the
Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the
Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and
Human Services; the Wellcome Trust, a global charity based in the UK working to improve health
globally; Germany’s Federal Ministry of Education and Research (BMBF); the UK Department of
Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) funded by the
UK Government Department of Health and Social Care (DHSC); the Bill & Melinda Gates Foundation,
and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of
the US National Institutes of Health (NIH) within the US Department of Health and Human
Services. CARB-X is investing up to US$480 million from 2016-2022 to support innovative
therapeutics, preventatives and rapid diagnostics. CARB-X funds only projects that target drugresistant
bacteria highlighted on the CDC’s Antibiotic Resistant Threats list, or the Priority Bacterial
Pathogens list published by the WHO, with a priority on those pathogens deemed Serious or Urgent
on the CDC list or Critical or High on the WHO list. CARB-X is headquartered at Boston University
School of Law. https://carb-x.org/. Follow us on Twitter @CARB_X
Disclaimer
Research reported in this press release is supported by CARB-X. CARB-X’s funding for this project is
sponsored by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by an award
from the Wellcome Trust. The content is solely the responsibility of the authors and does not
necessarily represent the official views of CARB-X or any of its funders.